Based on a highly innovative therapeutic concept ProFem develops new medicines for gynecological diseases which are characterized by a hitherto unmet medical need and high market potential. ProFem’s activities are currently focused on infectious diseases of the female lower genitourinary tract associated with the growth of biofilms.
R&D:About 150 million women worldwide are suffering constantly from recurrent vulvovaginal Candidosis (RVVC). This medical condition deteriorates the quality of life of infected women substantially, often for years, and currently cannot be treated successfully.
Riglergasse 4
1180 Wien
Vienna
Contact: Marion Noe-Letsching (PhD, MD, CEO)
Email: marion.noe@profem.at
Website